查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602822

抗惊厥药物市场：依药物类型、适应症划分 - 全球预测 2025-2030

Anticonvulsants Market by Drug types (AMPA, Barbiturate, Benzodiazepine), Indication (Anxiety, Bipolar Disorder, Borderline Personality Disorder) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗惊厥药市值为120.3亿美元，预计到2024年将达到130.7亿美元，复合年增长率为8.71%，到2030年将达到215.9亿美元。

抗惊厥药，也称为抗癫痫药，是主要用于预防和治疗与癫痫相关的癫痫发作的药物，也用于治疗双相情感障碍、偏头痛和神经病变疼痛。对抗惊厥药物的需求源自于神经系统疾病的日益普及以及对此类疾病进行有效管理的需要。这些药物广泛用于医院、诊所和居家医疗机构，为癫痫和其他神经系统疾病患者提供重要的治疗选择。对于医疗保健提供者和患者来说，最终用途范围已显着扩大，支持了有关药物依从性和副作用管理的可近性和患者教育的需求。市场成长主要是由药物发现的技术进步、诊断能力的提高以及对这些药物的认识和接受度的提高所推动的。此外，新型製剂和联合治疗的逐渐出现为市场渗透提供了潜在的机会。然而，严格的法律规范、潜在的副作用和高昂的治疗成本等挑战可能会阻碍市场成长。抗药性癫痫的适当治疗仍存在重大差距，凸显了创新和研究的潜在领域。此外，利用人工智慧开发个人化医疗方法和药物开发可以为业务成长开闢新的途径，旨在提高疗效并最大限度地减少副作用。鑑于抗惊厥药物市场的性质，公司应优先考虑策略伙伴关係关係、先进研发投资以及市场多元化，以保持相关性。经皮吸收贴片和鼻喷剂等给药方法的持续创新，以及对新作用机制的探索，正在显着影响市场动态，推动成长并解决神经治疗领域未满足的需求。

主要市场统计
基准年[2023] 120.3亿美元
预测年份 [2024] 130.7亿美元
预测年份 [2030] 215.9亿美元
复合年增长率（%） 8.71%

市场动态：揭示快速发展的抗惊厥药物市场的关键市场洞察

供需的动态交互作用正在改变抗惊厥药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 年轻人和老年族群中癫痫盛行率不断上升
    • 政府措施不断采取措施来支持癫痫意识
    • 扩大用于治疗癫痫以外的疾病
  • 市场限制因素
    • 疼痛管理替代方案的可用性
  • 市场机会
    • 抗癫痫药物的监管核准增加
    • 推出新一代抗癫痫药物
  • 市场问题
    • 供不应求与二代药专利到期

波特五力：驾驭抗惊厥药物市场的策略工具

波特五力：框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗惊厥药物市场的外部影响

外部宏观环境因素在塑造抗惊厥药物市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解抗惊厥药物市场的竞争格局

抗惊厥药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：抗惊厥药物市场供应商绩效评估

FPNV定位矩阵是评估抗惊厥药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製抗惊厥药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，抗惊厥药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 年轻人和老年人的癫痫盛行率增加
      • 政府努力支持提高癫痫意识
      • 扩大用于非癫痫疾病的治疗
    • 抑制因素
      • 疼痛管理替代方案的可用性
    • 机会
      • 抗惊厥药物的监管核准增加
      • 新一代抗癫痫药物的出现
    • 任务
      • 供不应求及二代药专利到期
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 抗惊厥药物市场：依药物类型

  • 介绍
  • AMPA
  • 巴比妥酸
  • 苯二氮平类
  • 氨基甲酸酯氨基甲酸酯抗惊厥药
  • 碳酸酐酶抑制剂
  • 二苯并氮卓
  • 三嗪

第七章 抗惊厥药物市场：依适应症分类

  • 介绍
  • 焦虑
  • 躁郁症
  • 边缘性人格障碍
  • 癫痫
  • 纤维肌痛
  • 偏头痛
  • 神经病变疼痛

第八章美洲抗惊厥药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太抗惊厥药市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲抗惊厥药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Astrazeneca PLC
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cadila Pharmaceuticals Limited
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Jazz Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lifecare Neuro Products Limited
  • Lundbeck A/S
  • Mankind Pharma Ltd.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Limited
Product Code: MRR-ED54C46E8048

The Anticonvulsants Market was valued at USD 12.03 billion in 2023, expected to reach USD 13.07 billion in 2024, and is projected to grow at a CAGR of 8.71%, to USD 21.59 billion by 2030.

Anticonvulsants, also known as antiepileptic drugs, are medications primarily used to prevent and treat seizures associated with epilepsy but are also used for bipolar disorder, migraines, and neuropathic pain. The necessity for anticonvulsants stems from the increasing prevalence of neurological disorders and the need for effective management of such conditions. These medications find broad application across hospitals, clinics, and homecare settings, offering critical therapeutic options for patients with epilepsy and other neurological conditions. The end-use scope largely extends to healthcare providers and patients, underlining the need for accessibility and patient education regarding medication adherence and side effects management. Market growth is significantly influenced by technological advancements in drug discovery, an increase in diagnostic capabilities, and heightened awareness and acceptance of these medications. Moreover, the progressive emergence of novel drug formulations and combination therapies offers potential opportunities for deeper market penetration. However, challenges such as stringent regulatory frameworks, potential side effects, and the high cost of treatment may hamper market growth. There is still a notable gap in adequate treatment for drug-resistant forms of epilepsy, highlighting a potential area for innovation and research. Furthermore, developing personalized medicine approaches and leveraging artificial intelligence for drug development could present new avenues for business growth, aiming to increase efficacy and minimize adverse effects. Given the nature of the anticonvulsants market, characterized by a competitive landscape with numerous players focusing on R&D and mergers, businesses must prioritize strategic partnerships, investment in advanced R&D, and market diversification to stay relevant. Continuous innovation in delivery methods, like transdermal patches or intranasal sprays, and exploring novel mechanisms of action can significantly influence market dynamics, propelling growth and addressing unmet needs in neurological treatment.

KEY MARKET STATISTICS
Base Year [2023] USD 12.03 billion
Estimated Year [2024] USD 13.07 billion
Forecast Year [2030] USD 21.59 billion
CAGR (%) 8.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anticonvulsants Market

The Anticonvulsants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of epilepsy among young and senior population
    • Rising government initiatives supporting epilepsy awareness
    • Expanding use in treating nonepileptic conditions
  • Market Restraints
    • Availability of substitutes options for pain management
  • Market Opportunities
    • Rising drug approvals of anticonvulsant drugs from regulatory bodies
    • Emergence of new-generation antiepileptic drugs
  • Market Challenges
    • Drug supply shortage and patent expiration of the second-generation drugs

Porter's Five Forces: A Strategic Tool for Navigating the Anticonvulsants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anticonvulsants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anticonvulsants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anticonvulsants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anticonvulsants Market

A detailed market share analysis in the Anticonvulsants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anticonvulsants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anticonvulsants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anticonvulsants Market

A strategic analysis of the Anticonvulsants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anticonvulsants Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Dr. Reddy's Laboratories Limited, Eisai Co., Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Jazz Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Lifecare Neuro Products Limited, Lundbeck A/S, Mankind Pharma Ltd., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Anticonvulsants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug types, market is studied across AMPA, Barbiturate, Benzodiazepine, Carbamate Anticonvulsants, Carbonic Anhydrase Inhibitor, Dibenzazepine, and Triazine.
  • Based on Indication, market is studied across Anxiety, Bipolar Disorder, Borderline Personality Disorder, Epilepsy, Fibromyalgia, Migraine, and Neuropathic Pain.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of epilepsy among young and senior population
      • 5.1.1.2. Rising government initiatives supporting epilepsy awareness
      • 5.1.1.3. Expanding use in treating nonepileptic conditions
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of substitutes options for pain management
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
      • 5.1.3.2. Emergence of new-generation antiepileptic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Drug supply shortage and patent expiration of the second-generation drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anticonvulsants Market, by Drug types

  • 6.1. Introduction
  • 6.2. AMPA
  • 6.3. Barbiturate
  • 6.4. Benzodiazepine
  • 6.5. Carbamate Anticonvulsants
  • 6.6. Carbonic Anhydrase Inhibitor
  • 6.7. Dibenzazepine
  • 6.8. Triazine

7. Anticonvulsants Market, by Indication

  • 7.1. Introduction
  • 7.2. Anxiety
  • 7.3. Bipolar Disorder
  • 7.4. Borderline Personality Disorder
  • 7.5. Epilepsy
  • 7.6. Fibromyalgia
  • 7.7. Migraine
  • 7.8. Neuropathic Pain

8. Americas Anticonvulsants Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anticonvulsants Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anticonvulsants Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astrazeneca PLC
  • 3. Bausch Health Companies Inc.
  • 4. Biocon Limited
  • 5. Cadila Pharmaceuticals Limited
  • 6. Cipla, Inc.
  • 7. Dr. Reddy's Laboratories Limited
  • 8. Eisai Co., Ltd.
  • 9. GlaxoSmithKline PLC
  • 10. Glenmark Pharmaceuticals Ltd.
  • 11. Jazz Pharmaceuticals, Inc.
  • 12. Johnson & Johnson Services, Inc.
  • 13. Lifecare Neuro Products Limited
  • 14. Lundbeck A/S
  • 15. Mankind Pharma Ltd.
  • 16. Merck KGaA
  • 17. Novartis AG
  • 18. Novo Nordisk A/S
  • 19. Otsuka Pharmaceutical Co., Ltd.
  • 20. Pfizer Inc.
  • 21. Sanofi S.A.
  • 22. Sunovion Pharmaceuticals Inc.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Wockhardt Limited

LIST OF FIGURES

  • FIGURE 1. ANTICONVULSANTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTICONVULSANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTICONVULSANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTICONVULSANTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AMPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CHINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 45. INDIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. INDONESIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 47. INDONESIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. JAPAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 49. JAPAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 51. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 53. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 55. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 57. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. TAIWAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 59. TAIWAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. THAILAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 61. THAILAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. VIETNAM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 63. VIETNAM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. DENMARK ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 68. DENMARK ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. EGYPT ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 70. EGYPT ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FINLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 72. FINLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. FRANCE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 74. FRANCE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. GERMANY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 76. GERMANY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ISRAEL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 78. ISRAEL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ITALY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 80. ITALY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 82. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NIGERIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 84. NIGERIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. NORWAY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 86. NORWAY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. POLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 88. POLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. QATAR ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 90. QATAR ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. RUSSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 92. RUSSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 94. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SPAIN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 98. SPAIN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWEDEN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 100. SWEDEN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 102. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. TURKEY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 104. TURKEY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 110. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023